Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis
J.R. Curtis, J.W. Baddley, and S. Yang et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis Arthritis Res Ther 13 2011 R155
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice
J. Anderson, L. Caplan, and J. Yazdany et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice Arthritis Care Res (Hoboken) 64 2012 640 647
Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data
J.R. Curtis, B. Chastek, and L. Becker et al. Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data Arthritis Res Ther 15 2013 404
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
P.S. Romano, L.L. Roos, and J.G. Jollis Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives J Clin Epidemiol 46 1993 1075 1079
Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis
E. Wu, L. Chen, and H. Birnbaum et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis Curr Med Res Opin 24 2008 2229 2240
Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: Evidence from clinical practice
R.J. Moots, B. Haraoui, and M. Matucci-Cerinic et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice Clin Exp Rheumatol 29 2011 26 34
Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis
L. Etemad, E.B. Yu, and L.A. Wanke Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis Manag Care Interface 18 2005 21 27
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
M.L. Hetland, I.J. Christensen, and U. Tarp et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 2010 22 32
